Floatz logo

rAd-p53

Metastatic Solid Tumor Cancer

MultiVir, Inc.Phase 1/2Dormant
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Metastatic Solid Tumor Cancer cohort.

Asset / SponsorPhaseRating
Capecitabine
MultiVir, Inc.
Phase 1/2CCC
Pembrolizumab
MultiVir, Inc.
Phase 1/2CCC
Nivolumab
MultiVir, Inc.
Phase 1/2CCC

Same molecule, other indications

rAd-p53 is also rated in:

hepatocellular carcinomaDormant
CCC
Indicative ·
53 / 100
View asset →
diabetes mellitusDormant
CCC
Indicative ·
53 / 100
View asset →
adult hepatocellular carcinomaDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →